Healthcare wait times have improved, report finds
A Health and Social Care (HSC) report found the inpatient waiting list fell from 2,799 at the end of 2023 to 2,207 at the end of 2024, a drop of more than 20%.
It also found more than three out of five patients were seen by the Medical Specialist Group (MSG) within the target time of eight weeks, a 1% improvement on the previous year.
MSG Chair Dr Steve Evans said the group was "determined to continue to do all we can with HSC to continue to reduce waiting times".
He said: "While we continue to increase the number of patients we care for, there has been no adverse impact on the standards of care.
"The average length of stay for a patient is just three days (against a target of less than six days) yet our emergency readmission rate is as low as 7% (against a target of less than 10%) which means that we are not discharging patients before they are ready to go home."
Dr Evans said recruiting specialists with the right experience continued to be a top priority.
The HSG said other 2024 Key Performance Indicators (KPIs) showed waiting times for radiology were above target with 95% of patients getting an x-ray or scan within six weeks of referral.
Gastroenterology and orthopaedics were the specialities with the longest waiting lists, the HSG added.
The report also highlighted delayed transfers of care days, which measure the time that patients stay in hospital after they are considered fit for discharge, either because a nursing or care home bed is not available or because they need extra care at home, was at 338 days against a target of 100.
Dr Peter Rabey, HSC Medical Director, said: "There are many positives that can be drawn from this latest KPIs report.
"The Emergency Department saw record numbers of admissions but continued to perform well and the number of hospital-acquired infections remains consistently low."
"We cannot control the rising demand for healthcare," he added.
"We do not have infinite financial, staff, ward or theatre resources, but we have created additional capacity through our ophthalmology waiting list initiative and this has had a positive impact."
Dr Rabey said more joint operations were taking place "than ever before" due to dedicated beds at De Havilland ward.
Follow BBC Guernsey on X and Facebook. Send your story ideas to channel.islands@bbc.co.uk.
Charity chairman steps down after 30 years
Geriatric specialist joins Guernsey health group
Social prescribing giving islanders 'purpose'
Health and Social Care
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24-06-2025
- Yahoo
Watchdog acted ‘irrationally' in registering private gender clinic, court told
The health watchdog's decision to register England's first private clinic offering gender treatment to young people was 'simply not open to it', the High Court has heard. Former nurse Susan Evans and a mother known as XX are taking legal action against the Care Quality Commission (CQC) over its decision to register the Gender Plus Hormone Clinic (GPHC) in Birmingham in January last year. The two are also challenging the regulator's decision to continue the clinic's registration and to allow it to prescribe cross-sex hormone treatment to 16 and 17-year-olds without conditions, made last December. The clinic, which was rated outstanding by the watchdog last year, treats people aged 16 and older, including through prescribing gender-affirming – masculinising or feminising – hormones, but, in line with the NHS, does not prescribe puberty blockers. Lawyers representing the two women told a hearing on Tuesday that the watchdog did not consider aspects that were 'obviously material' when making its decision, including the NHS's stance on hormone treatment for children aged 16 and 17 in light of the Cass Review. The watchdog is defending the claim, telling the court that it was 'abundantly clear that there was ample evidence' for its decision, while lawyers for the company which runs the clinic, Gender Plus Healthcare Limited, said the legal action was 'fatally flawed'. Opening the women's case on Tuesday, barrister Tom Cross KC said the clinic was believed to be the only hormone treatment provider to 16 and 17-year-olds in England, and that the claimants' concern was about safety, with Ms Evans previously stating she believed the registration 'creates a significant risk of a two-tier approach'. Mr Cross said: 'At arriving at the conclusion that the provider should continue to be registered without any conditions … the CQC has acted irrationally.' He added: 'It has not factored into its conclusion a number of aspects of the process on the NHS, informed by the Cass Review, which serve as important safeguards for children within the cohort and were obviously material.' The barrister said that had the CQC factored these in, it would have 'decided to exercise its power to halt the treatment' of under-18s, and that its decision was 'simply not open to them'. He claimed that 'at the very least' the court 'should require the CQC to think again about the adequacy of the safeguards'. Hormone treatment was previously provided on the NHS at the now-closed Gender Identity Development Service (Gids) run by the Tavistock and Portman NHS Foundation Trust, where Ms Evans previously worked. But a review published by Baroness Cass in April last year said that 'extreme caution' should be demonstrated when deciding to prescribe the treatment to 16 and 17-year-olds, and that there should be 'clear clinical rationale for providing hormones at this stage rather than waiting until an individual reaches 18'. The NHS has opened three specialist children's gender clinics and has plans for a further five covering the seven NHS regions in England by the end of 2026, but has said that all recommendations for hormone interventions must be endorsed by a national multi-disciplinary team (MDT). It is understood that the MDT has not yet received any recommendations for hormone treatment for 16 and 17-year-olds, since the Cass Review. GPHC was set up by Dr Aidan Kelly and is led by nurse consultant Paul Carruthers, who both worked at Gids, and has previously said it primarily treats patients aged between 16 and 25, using its own MDT. But Mr Cross said in written submissions that in the year up to June 2024, GPHC has 'accepted almost every single patient that it considered' for hormone treatment, and that the contrast with the NHS 'could not be more stark'. He said there were 'a number of key differences' between GPHC and the NHS safeguards, including that referrals to the former came from Dr Kelly's company, Kelly Psychology, which is unregulated. He said: 'It is, and ought to have been, obvious that the unregulated nature of the referrer enhanced the risk of patient safety.' He concluded: 'Either the CQC had to impose a condition which rationally ensured patient safety, or, if that were not possible, had to decide not to continue the registration.' Jamie Burton KC, for the CQC, said that there was 'ample evidence' that Kelly Psychology 'did not pose an unacceptable risk' to patients, and that a 'significant number' of those assessed by the company were not referred for treatment at GPHC. The court was told that the CQC found no evidence of 'improper decision making or anything that might flag a concern', and that the clinic was found to be 'committed to the safety and best interests of its patients'. He continued: 'CQC found GHPC to be acting in line with national guidance, including the NHS England 2024 Criteria. 'It found nothing to suggest that this was merely lip service or that GPHC management held an ideological commitment that was undermining its professional and regulatory commitments, or otherwise threatening the safety of patients.' He also said that the CQC 'had regard' to NHS processes, and that there could not be 'any legitimate doubt about the correctness of the ultimate outcome, or GPHC's continued registration'. He said: 'In its professional judgment, it found that the provider was taking reasonable steps to safeguard 16 and 17-year-olds by way of its existing processes.' Peter Mant KC, for Gender Plus Healthcare Limited, said that there was no legal requirement for a private provider to mirror NHS care and that the claimants' concerns 'do not have a high-quality evidence base'. He continued that the clinic's model was 'entirely consistent' with the Cass Review and NHS policy, and that patients 'no longer routinely have any input' from Kelly Psychology. He added that concerns related to the rate of accepting new patients were 'unjustified', and that the court should not 'go behind' the CQC's decision. The hearing before Mrs Justice Eady is expected to conclude on Wednesday, with a judgment expected in writing at a later date.
Business Upturn
12-06-2025
- Business Upturn
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to treating sickle cell disease and beta thalassemia. CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today shared new in vivo data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells (HSCs) with a single dose of proprietary targeted lipid nanoparticle (tLNP) in non-human primates (NHPs). This clinically validated approach targeting HBG1/2 promoters to upregulate fetal hemoglobin (HbF) is in pre-clinical development as a potential transformative in vivo gene editing medicine for the treatment of sickle cell disease and beta thalassemia. The Company reported these data in a presentation available today and will detail the data in a poster session on Saturday, June 14th 6:30 – 7:30 p.m. CEST (12:30 – 1:30 p.m. EDT) at the European Hematology Association (EHA) 2025 Congress in Milan, Italy. In this study, the Company's proprietary tLNP formulation delivered HBG1/2 promoter editing cargo to HSCs in NHPs. Latest data from this ongoing NHP study showed that at five months a single intravenous administration of Editas' tLNP resulted in mean on-target editing levels in the HBG1/2 promoter region of 58% in HSCs: well exceeding the predicted editing threshold of ≥25% required for therapeutic benefit. In addition to achieving therapeutically relevant editing levels, the biodistribution data in NHPs with Editas' tLNP continue to show significant de-targeting of the liver in contrast to standard LNPs. 'These data from our in vivo HSC program confirm our ability to achieve high efficiency delivery, therapeutically relevant editing levels and favorable biodistribution in NHPs. These data validate the further development of Editas' proprietary HSC-tLNP for editing of the HBG1/2 promoters for the treatment of sickle cell disease and beta thalassemia,' said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. Editas Medicine's in vivo HSC program targets HBG1/2 promoters to mimic naturally occurring mechanisms of hereditary persistence of fetal hemoglobin (HPFH) and utilizes proprietary AsCas12a to edit with high efficiency and minimize off-target editing. Editing the HBG1/2 promoters with AsCas12a with the investigational medicine reni-cel led to robust increases in HbF and total hemoglobin (Hb) in clinical trials. The presentation details are listed below. Abstracts can be accessed on the EHA website , and the presentation will be posted on the Editas Medicine website during the conference. Poster Presentation Details: Title: Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for β-hemoglobinopathies Date/Time: Saturday, June 14, 2025, 6:30 – 7:30 p.m. CEST/ 12:30 – 1:30 p.m. EDT Location: Allianz MiCo, Milano Convention Centre Session: Poster Session 2 About Editas Medicine As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit . Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
11-06-2025
- Yahoo
Fewer than 1 in 4 Colorado voters support Medicaid cuts
(Stock photo by) Just 21% of Colorado voters want Congress to decrease Medicaid spending, according to a poll released Tuesday. Concerns about gutted health care access come as U.S. Senate Republican leaders work to push through a tax and spending bill that would cut Medicaid by an estimated $625 billion over the next decade. The poll zeroed in on the 8th Congressional District, which includes the northern Denver metro area and parts of Weld County. In the district, where 1 in 4 residents receive Medicaid benefits, 63% of voters said they would be less likely to vote for a candidate who voted to cut Medicaid. SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX The 8th District is represented by Republican Gabe Evans, who voted in favor of the plan that would reduce federal Medicaid spending when it was brought to the U.S. House of Representatives in May. A spokesperson for Evans defended the vote, saying a proposed provision to institute part-time work requirements for some people to retain Medicaid eligibility would make 'the program more efficient by cutting out fraud, waste, and abuse.' 'Congressman Gabe Evans has been steadfast in his support of protecting Medicaid for the vulnerable populations it was created to serve — pregnant women, kids, and disabled people,' said spokesperson Delanie Bomar in a statement Tuesday. Evans, who was elected to the House last year, represents one of the country's few congressional swing districts. According to the poll, 42% of voters in the district want to see increased federal Medicaid spending, 20% want it to stay about the same and 28% want it to decrease. Medicaid, the state-federal health care program for lower-income people and some with disabilities, serves more than 70 million U.S. residents. The poll of 675 registered Colorado voters was conducted by Broomfield-based firm Magellan Strategies on behalf of the nonprofit Healthier Colorado. It has a margin of error of 3.7%. 'Politicians are saying that they want to cut Medicaid to make it better, but the poll shows clearly that voters aren't buying what they're selling,' said Jake Williams, CEO of Healthier Colorado. 'It shows that there's real political peril for any candidate who votes to cut Medicaid.' Bomar pointed to the poll's findings that many respondents, especially those who are Republicans or unaffiliated, said Medicaid 'should only be for U.S. citizens or legal residents, with some calling for stricter eligibility enforcement.' Immigrants who are in the U.S. unlawfully are not eligible for federal Medicaid benefits, but Colorado and 13 other states provide some state-funded coverage to immigrants lacking permanent legal status. Under the proposed federal cuts, an estimated 7.8 million people, most of them citizens or lawful residents, would lose access to Medicaid, according to the nonpartisan Congressional Budget Office. Some of the main reasons cited in the poll by respondents who said they have favorable opinions of Medicaid are the benefits it provides to low-income Coloradans, seniors, children, people with disabilities and single parents. 'The poll shows that Medicaid cuts would have devastating effects for both our health and economy here in Colorado,' Williams said. 'I also think it shows that Colorado voters aren't dummies.' SUPPORT: YOU MAKE OUR WORK POSSIBLE
